Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Obinutuzumab in Marginal Zone Lymphoma (OLYMP-1)

NCT03322865 is registered in ClinicalTrials.gov with Christian Buske as lead sponsor.

NCT NCT03322865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03322865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Obinutuzumab in Marginal Zone Lymphoma (OLYMP-1)
Lead sponsor
Christian Buske
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 23, 2018
Completion date
January 31, 2027
Enrollment
56 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

marginal zone lymphoma